Advanced Cancer Clinical Trial
Official title:
A Structured Early Palliative Care Intervention for Patients With Advanced Cancer - a Randomized Controlled Trial With a Nested Qualitative Study (SENS Trial)
It is assumed that an early palliative care structured by SENS (a systematic, problem-based
assessment system) in addition to standard oncology care compared with standard oncology care
alone relieves distress in patients with advanced cancer at the end of life.
The primary objective of the trial is to determine the effectiveness of early palliative care
intervention, structured by SENS (a systematic, problem-based assessment system) in addition
to standard oncology care, compared with standard oncology care alone to relieve distress a)
in patients with advanced cancer until death, and b) in caregivers. The secondary objectives
are to determine whether the introduction of SENS improves quality of life, prolongs overall
survival, ameliorates distress of caregivers, reduces health care costs and medical resource
utilization (less aggressive treatment in the last weeks of life).
Background
Intervention (performed by specialist palliative care teams): The structured approach
intervention is based on NCCN Practice Guidelines for Palliative Care, part of Gold Standard
Framework (GSF) and the WHO definition of Palliative Care. It supports the assessment of
areas and complexity of concerns from the patient perspective, determining priorities and
structures the support needed. SENS stands for: Symptom-management, instruction for self
administration of medication etc. End of life decision-making: explicit definition of own
goals and priorities; Network organization including anticipatory planning of emergency
situations
Support of the carers: implementation of support systems for the caring family members
The standardized intervention (based on prepared educational tool kit including a patient
prompt sheet) is performed by a palliative care physician and nurse collaboratively after
randomization and consent. The intervention is undertaken only once (after baseline
questionnaire and before first follow-up questionnaire). There is a total of 4 questionnaires
in the first 6 months. In addition, patients will receive usual oncology care throughout the
study period (see below).
Usual Oncology care (performed by oncological out- and inpatient clinics): Usual care
incorporates a routine assessment according to national protocols, which assesses overall
symptoms and current complaints from other domains. Participants assigned to usual care may
meet with the palliative care service on request according to established practice but
without following the SENS approach (subgroup analysis will be performed).
Main eligibility criteria
Patients >/= 18 years of age who signed informed consent with understanding of the study
procedures and the investigational nature of the study with one of the following cancer
types:
- Diagnosed within the last 16 weeks
- Metastatic or locally advanced, not amenable to curative treatment, non- small cell lung
cancer (NSCLC), or
- Metastatic or locally advanced, not amenable to curative treatment, colorectal cancer,
or
- Metastatic or locally advanced, not amenable to curative treatment, prostate cancer, or
- Metastatic or locally advanced, not amenable to curative treatment, breast cancer with
visceral and/or brain metastasis, or
- Metastatic or locally advanced, not amenable to curative treatment, bladder/ urothelium
cancer, or
- Metastatic or locally advanced, not amenable to curative treatment, pancreatic cancer
- Diagnosis is histologically confirmed
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2
Exclusion criteria
- Presence of delirium or dementia or other reason for lack of ability to give informed
consent
- Inability to communicate adequately in German
- Patient's lack of accountability, inability to appreciate the nature, meaning and
consequences of the study and to formulate his/her own wishes correspondingly
- Patients already receiving care from an inpatient palliative care service
Outcomes Primary outcomes
- Distress over six month as measured with the National Comprehensive Cancer Network
(NCCN) Distress thermometer Secondary outcomes
- Quality of life as measured by Functional Assessment of Cancer Therapy - General
(FACT-G)
- Palliative Outcome Scale (POS)
- Overall survival
- Location of death
- Health care utilization
Objective
The primary objective of the trial is to determine the effectiveness of early palliative care
structured by SENS (a systematic, problem-based assessment system) in addition to standard
oncology care compared with standard oncology care alone to relieve distress in patients with
advanced cancer at the end of life.
The secondary objectives are to determine whether the introduction of SENS improves quality
of life and prolongs overall survival in these patients, reduces health care costs and
medical resource utilization.
The primary objective of the nested qualitative study is to identify characteristics and
reasons for the added value as well as failure of a compulsory problem-based assessment
system (SENS) in advanced cancer patients.
Methods
Design Multicenter, two-arm, parallel-group, randomized-controlled trial with a nested
qualitative study (content analysis)
Experimental arm:
Palliative care with a structured approach (SENS model) based on the
bio-psycho-social-spiritual model of care. The approach supports the assessment of areas and
complexity of concerns from the patient perspective, determines the priority and structures
the support needed. The intervention is performed by palliative care physicians and nurses
collaboratively.
Control arm: Patients in the usual care group will receive routine oncology care throughout
the study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
Completed |
NCT01901237 -
Yoga for Adolescent and Young Adult Non-Curative Cancer Patients
|
N/A | |
Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 |